Business OpportunityUpdated on 20 April 2026
Personalised Cardiac Baseline (PCB)
Head of Business Development at Cardio.AI
Kyiv, Ukraine
About
Project Overview: Personalised Cardiac Baseline (PCB) – Shifting from General Standards to Individual Health Norms The Challenge: In modern cardiology, ECG analysis typically relies on universal population-wide standards. However, heart rhythm and electrical activity are highly individual. A "normal" reading for one person may mask early signs of pathology for another, or conversely, a benign individual variation might be misidentified as an abnormality. This lack of a "personalized norm" leads to late diagnoses of cardiovascular diseases (CVD) or unnecessary clinical interventions.
Proposed Solution: We propose to develop a Personalised Cardiac Baseline approach using our proprietary AI platform. Our technology is currently at TRL 8 and is capable of identifying over 75 classes of rhythm and conduction disorders with a precision and speed nearly five times greater than existing market alternatives. By analyzing extensive historical ECG datasets from our partners alongside our own data, we aim to redefine cardiac monitoring. Instead of comparing a patient to a "standard human," our AI will compare a patient to their own unique healthy baseline, allowing for the detection of subtle, patient-specific deviations. Level of Development (TRL): Our core AI engine is at TRL 8 (system complete and qualified). Within the PRECISEU framework, we intend to apply this mature technology to create and validate new clinical protocols for preventive cardiology.
Expected Impact & Alignment with PRECISEU: Health Data Solutions: Our project directly addresses the call’s objective to maximize the value of health data. We transform raw ECG data into actionable, personalised insights. Personalised Medicine: We move the needle from "one-size-fits-all" diagnostics to a patient-centric model, which is the core mission of PRECISEU. Impact on Field: By perfecting preventive protocols, we can significantly reduce the burden of CVD through earlier and more accurate detection, ultimately improving patient outcomes and healthcare efficiency across European regions.
Stage
- TRL 8
Topic
- Cardiovascular
Sector
- Health data
- AI
- Diagnostics
Type
- Research collaboration
- Co-development
- Consortium partners
Attached files
Organisation
Similar opportunities
Business Opportunity
Looking for PRECISEU consortium partners in personalised prevention and real-world validation
- AI
- TRL 6
- TRL 7
- Other
- Other
- Physiology
- Health data
- Co-development
- Consortium partners
- Research collaboration
- Diseases of the nervous system / neurology
- Mental and behavioural disorders / psychiatry /psychology
Daiva Kuizinaite
President, Lithuanian Nature Therapy Association (LGTA) at Lithuanian Nature Therapy Association
Kaunas Vilnius, Lithuania
Business Opportunity
- TRL 6
- Diseases of the nervous system / neurology
- Mental and behavioural disorders / psychiatry /psychology
Fabio Bianco
CEO at BrainDTech Spa
Milano, Italy
Business Opportunity
AI-powered Digital Twin for Personalised Vascular Intervention Planning
- AI
- TRL 6
- ATMPs
- Health data
- Cardiovascular
- Co-development
- Consortium partners
- Research collaboration
Leonardo Geronzi
CEO at LivGemini
Viterbo, Lazio, Italy